Granted Patent B2

US 12,251,367 · App. 18/518,044 · Granted Mar 18, 2025

Inventors: Bernard Cuenoud (Cully, CH); Mojgan Masoodi (Eclublens, CH)

Assignee: SOCIÉTÉ DES PRODUITS NESTLÉ S.A.

A61K31/21A23K20/158A23L33/12A23V2002/00

Abstract

Claims (22)

1. A method of treating an individual having a brain energy deficiency condition or disease, the method comprising administering a composition comprising medium-chain triglycerides (MCTs) to the individual, wherein the MCTs comprise:

a MCT comprising three fatty acid moieties each with 8 carbon atoms (MCT-C8); and

a MCT comprising three fatty acid moieties each with 10 carbon atoms (MCT-C10);

wherein the ratio of the MCT-C8 to the MCT-C10 is from 10:90 to 90:10 (mol/mol), and

wherein the combined amount of MCT-C 8 and MCT-C 10 is at least 50 mol % of the MCTs in the composition, and

wherein the composition provides increased ketones and/or fatty acids as compared to a composition comprising MCTs comprising three fatty acids moieties each with a mix of C8 and C10 moieties attached and having the same C8/C10 ratio and molar amounts.

2. The method according to claim 1 wherein the ratio of MCT-C8 to MCT-C10 is 20:80 to 85:15 (mol/mol).

3. The method according to claim 1 wherein the combined amount of MCT-C8 and MCT-C10 is at least 90 mol % of the MCTs in the composition.

4. A method of treating an individual having a brain energy deficiency condition or disease, the method comprising administering a composition comprising medium-chain triglycerides (MCTs) to the individual, wherein the MCTs comprise:

a MCT comprising three fatty acid moieties each with 8 carbon atoms (MCT-C8); and

a MCT comprising three fatty acid moieties each with 10 carbon atoms (MCT-C10); and

wherein the ratio of the MCT-C8 to the MCT-C10 is from 50:50 to 67:33 (mol/mol), and

wherein the composition provides increased ketones and/or fatty acids as compared to a composition comprising MCTs comprising three fatty acids moieties each with a mix of C8 and C10 moieties attached and having the same C8/C10 ratio and molar amounts.

5. The method according to claim 1 , wherein the three fatty acid moieties each with 8 carbon atoms are octanoic acid moieties, and/or the three fatty acid moieties each with 10 carbon atoms are decanoic acid moieties.

6. The method according to claim 1 , wherein the composition further comprises one or more agents that promote or sustain neurologic health or enhance cognitive function, wherein the one or more agents are selected from the group consisting of vitamins, choline, phosphatidylserine, alpha-lipoic acid, CoQ10, acetyl-L-carnitine, herbal extracts, omega-3 or omega-6 polyunsaturated fatty acids, aliphatic ester, fish oil extracts, and mixtures thereof.

7. The method according to claim 4 , wherein the three fatty acid moieties each with 8 carbon atoms are octanoic acid moieties, and/or the three fatty acid moieties each with 10 carbon atoms are decanoic acid moieties.

8. The method according to claim 4 , wherein the composition further comprises one or more agents that promote or sustain neurologic health or enhance cognitive function, wherein the one or more agents are selected from the group consisting of vitamins, choline, phosphatidylserine, alpha-lipoic acid, CoQ10, acetyl-L-carnitine, herbal extracts, omega-3 or omega-6 polyunsaturated fatty acids, aliphatic ester, fish oil extracts, and mixtures thereof.

9. The method according to claim 1 , wherein the ratio of the MCT-C8 to the MCT-C10 is 58:42 to 62:38 (mol/mol).

10. The method according to claim 1 , wherein the condition or disease is selected from the group consisting of a brain energy deficiency, a neurological condition, migraine, memory disorder, age-related memory disorder, brain injury, stroke, amyloid lateral sclerosis, multiple sclerosis, cognitive impairment, cognitive impairment post-intensive care, age-induced cognition impairment, Alzheimer's disease, Parkinson's disease, Huntingdon's disease, an inherited metabolic disorder, bipolar disorder, schizophrenia, epilepsy and combinations thereof.

11. The method according to claim 4 , wherein the condition or disease is selected from the group consisting of a brain energy deficiency, a neurological condition, migraine, memory disorder, age-related memory disorder, brain injury, stroke, amyloid lateral sclerosis, multiple sclerosis, cognitive impairment, cognitive impairment post-intensive care, age-induced cognition impairment, Alzheimer's disease, Parkinson's disease, Huntingdon's disease, an inherited metabolic disorder, bipolar disorder, schizophrenia, epilepsy and combinations thereof.

12. The method according to claim 10 , wherein the inherited metabolic disorder is selected from the group consisting of glucose transporter type 1 deficiency syndrome, pyruvate dehydrogenase complex deficiency, and combinations thereof.

13. The method according to claim 11 , wherein the inherited metabolic disorder is selected from the group consisting of glucose transporter type 1 deficiency syndrome, pyruvate dehydrogenase complex deficiency, and combinations thereof.

Assignments (2)

Priority Claims (1)

Continuity (3)

References Cited (43)